血清巯基蛋白酶抑制肽C诊断肝硬化肾受损的价值  

Diagnostic value of serum cystatin C for estimating renal function in patients with cirrhosis.

作　　者：邹义君[1] 王烜[1] 李晓云[1] 

机构地区：[1]泸州医学院附属医院消化内科,四川泸州646000

出　　处：《临床肝胆病杂志》2006年第5期363-364,共2页Journal of Clinical Hepatology

摘　　要：探讨血清巯基蛋白酶抑制肽C(CysC)对失代偿期肝硬化患者肾受损的诊断价值。根据24h肌酐清除率(Ccr)将92例肝硬化患者分为肾功正常组、代偿组和肝肾综合征(HRS)组;上述所有患者均检测血肌酐(Scr)、CysC和Ccr;CysC采用颗粒增强免疫比浊法(PETIA)。结果显示血清CysC的浓度在代偿组和HRS组明显高于肾功正常组(P<0．001);而Scr的浓度在代偿组和肾功正常组之间无明显差异(P>0．05),HRS组Scr的浓度明显高于代偿组和肾功正常组(P<0．001);Ccr与CysC和Scr呈负相关(r分别为-0．780和-0．699,P<0．01)。说明血清CysC的测定对肝硬化患者肾功能损害具有诊断价值,尤其对轻中度肾受损的早期诊断明显优于Scr。To study the diagnostic value of serum cystatin C（CysC） for evaluation of renal function in patients with decompensate cirrhosis. 92 patients with cirrhosis were divided into three groups according to creatinine clearance rate （Ccr）, normal renal function group, functional compensation group and hepaorenal syndrome （HRS） group. Serum CysC, serum creatinine （Scr） and Ccr were assayed in all patients. CysC was determined by the particle enhanced turbidimer/trie immunoassay （PETIA）, The levels of Serum CysC in functional compensation group and hepatorenal syndrome group were significantly higher than those in normal renal function group （P 〈0.001 ）, However, the levels of Scr in functional compensation group were not significantly higher than that in normal renal function group （ P 〉 0.05）. And the levels of Scr in hepatorenal syndrome group were significantly higher than that in normal renal function group and functional compensation group （ P 〈 0.001 ）, Ccr negatively correlated with CysC and Scr （ r = - 0.780 and - 0. 699,P 〈 0.01 , respectively）, Serum CysC determination could be a valuable tool for estimating renal function in patients with cirrhosis, particularly for early diagnosis of slightly and moderately impaired renal function.

关 键 词：巯基蛋白酶抑制肽C 肌酐清除率 肾功能损害 肝肾综合征 

分 类 号：R575.2[医药卫生—消化系统]